Other
Net unrealized gains (losses) on securities still held
Kailera Therapeutics Net unrealized gains (losses) on securities still held decreased by 12583.3% to -$761.00K in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
How to read this metric
An increase reflects positive market performance of the company's investment portfolio, potentially signaling latent liquidity.
Detailed definition
The change in the fair value of investment securities held by the company that are classified as available-for-sale or s...
Peer comparison
Standard for companies with significant cash reserves invested in marketable securities.
Metric ID:
other_other_comprehensive_income_unrealized_holding_gain_503fecHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | -$6.00K | -$761.00K |
| QoQ Change | — | <-999% |
| YoY Change | — | <-999% |
Range-$761.00K – -$6.00K
Avg YoY Growth<-999%
Median YoY Growth<-999%
Net unrealized gains (losses) on securities still held at Other Companies
Frequently Asked Questions
- What is Kailera Therapeutics 's net unrealized gains (losses) on securities still held?
- Kailera Therapeutics (KLRA) reported net unrealized gains (losses) on securities still held of -$761.00K in Q1 2026.
- What does net unrealized gains (losses) on securities still held mean?
- The change in value of investment holdings that have not yet been sold.